Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

566.85INR
8 Feb 2016
Change (% chg)

-- (--)
Prev Close
Rs566.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,318,069
52-wk High
Rs752.85
52-wk Low
Rs540.05

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a pharmaceutical company. The Company's business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company offers APIs, formulations and veterinary products. As of March 31, 2015, the Company offered its services across five continents across the world. It offers... (more)

Overall

Beta: 0.48
Market Cap(Mil.): Rs458,014.00
Shares Outstanding(Mil.): 803.32
Dividend: 2.00
Yield (%): 0.35

Financials

  CIPL.NS Industry Sector
P/E (TTM): 27.55 31.82 38.73
EPS (TTM): 20.69 -- --
ROI: 14.46 15.16 14.47
ROE: 14.98 15.92 15.40
Search Stocks

Baxalta-Coherus Enbrel biosimilar succeeds in late-stage study

Baxalta Inc and Coherus Biosciences Inc said their experimental biosimilar of Amgen Inc's arthritis drug Enbrel met the main goal in a late-stage study.

11 Jan 2016

UPDATE 1-Baxalta-Coherus Enbrel biosimilar succeeds in late-stage study

Jan 11 Baxalta Inc and Coherus Biosciences Inc said their experimental biosimilar of Amgen Inc's arthritis drug Enbrel met the main goal in a late-stage study.

11 Jan 2016

UPDATE 1-India's Cipla expects lower growth in second half of 2016

MUMBAI, Nov 5 Cipla Ltd, India's third-largest drugmaker by sales, said its sales for the rest of this year would be lower than that in the first half, after September-quarter earnings came in below analysts' expectations.

05 Nov 2015

India's Cipla Q2 net profit lags estimates

MUMBAI, Nov 5 Cipla Ltd, India's third-largest drugmaker by sales, reported a second-quarter net profit slightly below analysts estimates, as expenses rose.

05 Nov 2015

BUZZ-India's Cipla falters on US FDA letter, snapping 2-day rally

** Cipla Ltd, India's fourth-largest drugmaker by sales, closes down 2.1 pct; snaps two-day rally of 2.6 pct

20 Oct 2015

BUZZ-India's Cipla falls; traders cite FDA concerns over InvaGen plant

** Cipla, India's fourth-largest drugmaker by sales, falls as much as 3 pct to 660 rupees

14 Oct 2015

Cipla ties up with Serum Institute to sell vaccines in South Africa

MUMBAI Cipla Ltd , India's fourth-largest drugmaker by sales, said on Thursday it had agreed to an exclusive deal with Serum Institute of India to supply vaccines to South Africa, adding a new market to their partnership in India and Europe.

08 Oct 2015

India's Cipla ties up with Serum Institute to sell vaccines in South Africa

MUMBAI Cipla Ltd, India's fourth-largest drugmaker by sales, said on Thursday it had agreed to an exclusive deal with Serum Institute of India to supply vaccines to South Africa, adding a new market to their partnership in India and Europe.

08 Oct 2015

India's Cipla ties up with Serum Institute to sell vaccines in South Africa

MUMBAI, Oct 8 Cipla Ltd, India's fourth-largest drugmaker by sales, said on Thursday it had agreed to an exclusive deal with Serum Institute of India to supply vaccines to South Africa, adding a new market to their partnership in India and Europe.

08 Oct 2015

BRIEF-India's Cipla says unit in definitive agreement with Biopharma SPA for JV in Algeria

* Says unit Cipla (EU) Ltd in definitive agreement with Biopharma SPA for JV in Algeria Source text for Eikon: http://bit.ly/1RtLw4O Further company coverage:

07 Oct 2015

Earnings vs. Estimates

Search Stocks